Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market - Industry Trends and Forecast to 2029

Market Analysis and Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 agonists) are well-known as effective therapy for type 2 diabetes. GLP-1 RAs stimulate GLP-1 receptors, which increase insulin production and decrease glucagon release. Although all GLP-1 RAs work in the same way, they differ in terms of formulations, administration, injectable methods, and dosages. With six GLP-1 RAs currently available in Europe (immediate-release exenatide, lixisenatide, liraglutide; prolonged-release exenatide, dulaglutide, and semaglutide), each with their own characteristics and administration requirements, physicians caring for patients in their routine practise face the challenge of being aware of all of this information so they can select the agent that is most suitable for their patient and use it in an efficient and optimal manner

The glucagon-like peptide 1 (GLP-1) agonists is supportive and aims to reduce the severity of the symptoms. Data Bridge Market Research analyses that the glucagon-like peptide 1 (GLP-1) agonists market was valued at 12.55 billion in 2021 and is likely to reach USD 20.15 billion by 2029, and will grow at a CAGR of 6.10% during the forecast period of 2022 to 2029.

Report Scope and Market Segmentation

Glucagon-Like Peptide 1 (GLP-1) Agonists Market Dynamics

Drivers

  Major factors that are expected to boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the forecast period are as follows:

• Rise in the cases of type 2 diabetes, obesity and related disorders

The overall influence of individual-level factors, such as the population's increasing median age and health factors, such as rising obesity and inactivity rates among people, has resulted in an increase in the diabetes population over time.

• Growing adaptation of unhealthy lifestyle and genetic history of diabetes disorders

Rise in the hectic lifestyle and unbalanced food diet and the hereditary history of diabetes disorders which upsurges the danger of growing diabetes.

• The obtainability of the treatment

Growing number of middle-class households, rise in the per capita income and increasing expenditure are one of the main contributors of the market growth.

Opportunities               

In addition, the enhanced healthcare infrastructure, technological developments, and the accessibility of skilled medical professionals will further provide potential opportunities for the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the coming years.

Restraints/Challenges

On the flip side, strict FDA and other regulatory guidelines for the approval of new drug is further projected to impede he growth of the glucagon-like peptide 1 (GLP-1) agonists market in the timeline period. However, the dearth of suitable insurance policies might further challenge the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the near future.

This glucagon-like peptide 1 (GLP-1) agonists market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on glucagon-like peptide 1 (GLP-1) agonists market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The glucagon-like peptide 1 (GLP-1) agonists market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on Glucagon-Like Peptide 1 (GLP-1) Agonists Market

The COVID-19 has positively affected the glucagon-like peptide 1 (GLP-1) agonists market. During the lockdowns and isolation during the pandemic complicated the diabetes management and medication adherence. Glucagon-like peptide 1 (GLP-1) agonists market promises due to its anti-inflammatory and anti-obesogenic qualities, as well as pulmonary protection and a positive impact on gut microbiota composition. Taking everything into account, glucagon-like peptide 1 (GLP-1) agonists market appear to be promising options for the treatment of COVID-19-infected patients with or without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) medications during COVID-19 pandemics.

Recent Development                                                        

• In November 2021, the Preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors was presented at ObesityWeek 2021, according to Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders.

Global Glucagon-Like Peptide 1 (GLP-1) Agonists Market Scope

The glucagon-like peptide 1 (GLP-1) agonists market is segmented on the basis of drugs, brand, route of administration and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs 

• Exenatide
• Liraglutide
• Dulaglutide
• Lixisenatide

On the basis of drugs, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into exenatide, liraglutide, dulaglutide, lixisenatide.

Brand

• Byetta
• Bydureon
• Victoza
• Trulicity
• Lyxumia

On the basis of brand, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into byetta, bydureon, victoza, trulicity, lyxumia.

Route of Administration

• Oral
• Parenteral
• Others

On the basis of route of administration, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into oral, parenteral, others.

End Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end users, the glucagon-like peptide 1 (GLP-1) agonists market is segmented into hospitals, specialty clinics, others.

Glucagon-Like Peptide 1 (GLP-1) Agonists Market Regional Analysis/Insights

The glucagon-like peptide 1 (GLP-1) agonists market is analysed and market size insights and trends are provided by country, drugs, brand, route of administration and end users as referenced above.

The countries covered in the glucagon-like peptide 1 (GLP-1) agonists market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the healthcare. Furthermore, the growing research and development. Furthermore, the occurrence of major key players will further boost the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region during the forecast period. Asia-Pacific projected to observe significant amount of growth in the glucagon-like peptide 1 (GLP-1) agonists market due to the rise in the incidence cases of diabetes and other related disorders. Moreover, the growing number of generic drugs is anticipated to propel the growth of the glucagon-like peptide 1 (GLP-1) agonists market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Glucagon-Like Peptide 1 (GLP-1) Agonists Market Share Analysis

The glucagon-like peptide 1 (GLP-1) agonists market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to glucagon-like peptide 1 (GLP-1) agonists market.

Some of the major players operating in the glucagon-like peptide 1 (GLP-1) agonists market are:

• Lilly (US)
• Novo Nordisk A/S (Denmark)
• AstraZeneca (US)
• Sanofi (US)
• F. Hoffmann-La Roche Ltd (Switzerland)

SKU-52893